BETA

Q2 FY27 Consolidated Revenue ₹137.49Cr vs ₹103.39Cr (▲33% YoY) EBITDA ₹30.28Cr vs ₹16.76Cr (▲81% YoY) PAT ₹19.26Cr vs ₹12.22Cr (▲58% YoY) EBITDA Margin 22% vs 16% (▲600bps)

Current scenario - Beta Drugs Limited reported Q2 and H1 FY27 earnings, highlighting a revenue growth of 29.2% for H1 FY27 compared to H1 FY26. - EBITDA margin grew slightly from 23.08% to 23.18%, while PAT increased significantly by 45% from INR24 crores to INR34 crores. - The management addressed the trade margin capping on MRP, stating the overall impact on the company will be zero or negligible as scheduled and non-scheduled drugs are largely unaffected. Changes in trends - Own-branded business grew by 17% in H1 FY27, with Oral Solid Forms (OSD) contributing up to 50% of the total business. - Nivian Lifesciences delivered a strong growth of 75% (from INR18 crores to INR31 crores) in H1 FY27. - API business and Contract Manufacturing (CMO) business grew by 29% and 21% respectively in H1 FY27. Management Guidance & Outlook - Management maintains a guidance of 20% to 25% growth for the next three to five years with sustained EBITDA margins between 23% to 24%. - The company expects full-year FY27 branded oncology sales to reach INR150 crores and export sales to be in the range of INR90 crores to INR100 crores. - CMO business for FY27 is guided in the range of INR180 crores to INR190 crores. Capex & Growth Drivers - The backward-integrated API and intermediate plant is expected to go live by December/January, enhancing self-reliance and boosting margins. - In exports, 76 new dossiers were filed in different geographies, including four in Europe, with a pipeline of 872 new registrations. - The company is evaluating the biosimilar market and capital-efficient strategies, alongside potential oncology manufacturing outside India.

- H1 FY27 Revenue grew 29.2% YoY to ₹263 Cr vs ₹204 Cr in H1 FY26. - EBITDA stood at ₹61 Cr (23.2% margin) vs ₹47 Cr YoY; PAT increased to ₹34 Cr vs ₹24 Cr. - Branded Oncology up 17%; API grew ~30% with new capacity expected in Q4 FY27.

- H1 FY27 Consolidated Revenue ₹263.04 Cr vs ₹203.60 Cr (▲29.2% YoY) - EBITDA ₹61.00 Cr vs ₹47.00 Cr (▲29.8% YoY) - PAT ₹34.30 Cr vs ₹23.90 Cr (▲43.5% YoY) - EBITDA Margin 23.18% vs 23.08% (▲10 bps) - Management guided FY27 Revenue at ₹535+ Cr with 23%-24% EBITDA margins (quarterly table unreadable in filing)

Concall Schedule Concall Date: 22nd October 2026 Concall Time: 04:00 PM IST

Concall Schedule Concall Date: 22nd October 2026 Concall Time: 04:00 PM IST

- Beta Drugs received regulatory approvals for its oncology portfolio in Azerbaijan across multiple dosage forms including injectables, tablets, capsules, and oral suspensions. - The company has already filed 15 oncology product dossiers and expects another 15 to be ready for filing within the next month. - Beta Drugs aims to secure initial oncology business from Azerbaijan during the current financial year.

- Concall Schedule - Concall Date: September 17, 2026 - Concall Time: 4:00 pm IST - Beta Drugs Ltd. will participate in the Valorem CXO Meet, a virtual group meeting with Valorem Advisors. - The company achieved a 5-year revenue CAGR of 27% and EBITDA CAGR of 25%. - Beta Drugs is targeting a ~25% revenue CAGR through FY30.

- The 21st Annual General Meeting (AGM) of Beta Drugs Limited will be held on Wednesday, 30th September, 2026, at 10:30 a.m. at its registered office. - The Notice of AGM and Annual Report for FY 2025-26 will be submitted to the exchange.

- Board Meeting held on 3rd September 2026 approved the calling of the 21st Annual General Meeting (AGM). - The AGM is scheduled for Wednesday, 30th September 2026, at 10:30 A.M. - Book Closure Period is from 24th September 2026 to 30th September 2026. - Approved the appointment of Charu Jindal & Co as Cost Auditor and V.K. Srivastva & Associates as Internal Auditor for FY 2026-27. - Re-appointed Statutory Auditor M/s Khurana Sharma and Co for FY 2026-27 to 2027-28. - Re-appointed Mr. Ashutosh Shukla as Whole-Time Director from 20th January 2027 to 19th January 2032.

- Board approved the allotment of 35,383 Bonus Equity Shares of face value INR 10 each to holders of Compulsorily Convertible Debentures (CCDs) upon their conversion into Equity Shares. - Decision made at the Board meeting on August 18, 2026.

- Consolidated Revenue ₹125.55 Cr vs ₹100.21 Cr (▲25.28% YoY) - EBITDA ₹27.37 Cr vs ₹19.71 Cr (▲38.86% YoY) - PAT ₹16.49 Cr vs ₹11.70 Cr (▲40.94% YoY) - EBITDA Margin 21.80% vs 19.67% (▲213 bps)

- Consolidated Revenue ₹125.55Cr vs ₹100.21Cr (▲25.3% YoY) - EBITDA (excl. other income) ₹27.37Cr vs ₹19.70Cr (▲38.9% YoY) - PAT ₹16.49Cr vs ₹11.70Cr (▲40.9% YoY) - EBITDA Margin 21.80% vs 19.66% (▲214bps)

- Trading window closed for Directors, Officers, Designated Employees, and their immediate relatives. - Closure effective from July 1, 2026. - Reopens 48 hours after the declaration of Un-Audited Financial Results for Q1 ended June 30, 2026.